Given that TP53 mutation status is closely related to GI and it has been proposed as a biomarker with prognostic value in lung cancer (Zhou et al., 2019; Freudenstein et al., 2020), we further evaluated the performance between the newly developed GI-lncRNAs and TP53 mutation status in predicting the OS of patients with LUAC. Here, TP53 is linked to lung carcinoma.